[go: up one dir, main page]

WO2004091630A8 - 眼に適用する疾患治療剤 - Google Patents

眼に適用する疾患治療剤

Info

Publication number
WO2004091630A8
WO2004091630A8 PCT/JP2004/005479 JP2004005479W WO2004091630A8 WO 2004091630 A8 WO2004091630 A8 WO 2004091630A8 JP 2004005479 W JP2004005479 W JP 2004005479W WO 2004091630 A8 WO2004091630 A8 WO 2004091630A8
Authority
WO
WIPO (PCT)
Prior art keywords
eye
remedies
estrogen
diseases
serm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2004/005479
Other languages
English (en)
French (fr)
Other versions
WO2004091630A1 (ja
Inventor
Shinseiro Okamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Medicine Research Institute
Original Assignee
Advanced Medicine Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2004/004709 external-priority patent/WO2004093882A1/ja
Priority to AT04727990T priority Critical patent/ATE488240T1/de
Priority to EP04727990A priority patent/EP1621199B8/en
Priority to AU2004229291A priority patent/AU2004229291A1/en
Priority to JP2005505476A priority patent/JP4564920B2/ja
Priority to DE602004030103T priority patent/DE602004030103D1/de
Priority to CA002527175A priority patent/CA2527175A1/en
Application filed by Advanced Medicine Research Institute filed Critical Advanced Medicine Research Institute
Publication of WO2004091630A1 publication Critical patent/WO2004091630A1/ja
Priority to US11/252,013 priority patent/US20060111318A1/en
Anticipated expiration legal-status Critical
Publication of WO2004091630A8 publication Critical patent/WO2004091630A8/ja
Priority to US13/039,147 priority patent/US20110223269A1/en
Priority to US13/039,127 priority patent/US20110212199A1/en
Priority to US13/039,140 priority patent/US20110212200A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

　エストロゲンまたはその代謝物などの性ステロイドホルモン、その誘導体、構造類似体、エストロゲン作用物質またはＳＥＲＭ又はノンフェミナイジングエストロゲン（ノンホルモナールエストロゲン）を含有する点眼剤または洗眼剤等の形態にある各種疾患の治療剤。優れた治療効果を有し、副作用の低減された、眼に適用する疾患治療剤を提供できる。
PCT/JP2004/005479 2003-04-18 2004-04-16 眼に適用する疾患治療剤 Ceased WO2004091630A1 (ja)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AT04727990T ATE488240T1 (de) 2003-04-18 2004-04-16 Mittel zur behanldung von krankheiten zur aufbringung auf das auge
EP04727990A EP1621199B8 (en) 2003-04-18 2004-04-16 Remedies for diseases to be applied to eye
AU2004229291A AU2004229291A1 (en) 2003-04-18 2004-04-16 Remedies for diseases to be applied to eye
JP2005505476A JP4564920B2 (ja) 2003-04-18 2004-04-16 眼に適用する疾患治療剤
DE602004030103T DE602004030103D1 (de) 2003-04-18 2004-04-16 Mittel zur behanldung von krankheiten zur aufbringung auf das auge
CA002527175A CA2527175A1 (en) 2003-04-18 2004-04-16 Remedies for diseases to be applied to eye
US11/252,013 US20060111318A1 (en) 2003-04-18 2005-10-18 Agent for treating eye diseases
US13/039,140 US20110212200A1 (en) 2003-04-18 2011-03-02 Agent for treating eye diseases
US13/039,127 US20110212199A1 (en) 2003-04-18 2011-03-02 Agent for treating eye diseases
US13/039,147 US20110223269A1 (en) 2003-04-18 2011-03-02 Agent for treating eye diseases

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
JP2003114969 2003-04-18
JP2003-114969 2003-04-18
JP2003-132910 2003-05-12
JP2003132910 2003-05-12
JP2003-329165 2003-09-19
JP2003329165 2003-09-19
JP2003354135 2003-10-14
JP2003-354135 2003-10-14
JPPCT/JP04/004709 2004-03-31
PCT/JP2004/004709 WO2004093882A1 (ja) 2003-04-18 2004-03-31 眼に適用する疾患治療剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/252,013 Continuation-In-Part US20060111318A1 (en) 2003-04-18 2005-10-18 Agent for treating eye diseases

Publications (2)

Publication Number Publication Date
WO2004091630A1 WO2004091630A1 (ja) 2004-10-28
WO2004091630A8 true WO2004091630A8 (ja) 2005-11-24

Family

ID=33304160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/005479 Ceased WO2004091630A1 (ja) 2003-04-18 2004-04-16 眼に適用する疾患治療剤

Country Status (7)

Country Link
EP (6) EP2305308A1 (ja)
JP (2) JP4564920B2 (ja)
AT (1) ATE488240T1 (ja)
AU (1) AU2004229291A1 (ja)
CA (1) CA2527175A1 (ja)
DE (1) DE602004030103D1 (ja)
WO (1) WO2004091630A1 (ja)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305308A1 (en) * 2003-04-18 2011-04-06 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
MX2007010359A (es) * 2005-02-24 2008-04-04 Diffusion Pharmaceuticals Llc Trans carotenoides, su sintesis, formulacion y usos.
WO2006127987A2 (en) * 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
US8987241B2 (en) * 2009-06-19 2015-03-24 Altos Vision Limited Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application
US10130689B2 (en) 2009-06-22 2018-11-20 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
JP5885670B2 (ja) * 2009-12-11 2016-03-15 アルデイラ セラピューティクス， インコーポレイテッド 黄斑変性の処置のための組成物および方法
WO2011152869A1 (en) 2010-06-02 2011-12-08 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
CN105073714A (zh) 2012-12-20 2015-11-18 奥尔德拉医疗公司 迫位原醇
JP6514114B2 (ja) 2013-01-23 2019-05-15 アルデイラ セラピューティクス， インコーポレイテッド 毒性アルデヒド関連疾患および処置
KR20150120380A (ko) 2013-01-25 2015-10-27 알데이라 테라퓨틱스, 아이엔씨. 황반 변성의 치료에서 신규한 트랩
WO2017035077A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
CN116531400A (zh) 2016-02-28 2023-08-04 奥尔德拉医疗公司 用环糊精治疗过敏性眼部病状
CN109152839A (zh) 2016-03-24 2019-01-04 扩散药品有限公司 双极性反式类胡萝卜素连同化疗和放射治疗在治疗癌症中的用途
EP3454858A4 (en) 2016-05-09 2020-01-15 Aldeyra Therapeutics, Inc. COMBINATION TREATMENT OF FLAMMABLE CONDITIONS AND DISEASES OF THE EYE
AU2018234919A1 (en) 2017-03-16 2019-09-19 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
JP6923917B2 (ja) * 2017-09-21 2021-08-25 国立大学法人福井大学 白内障の予防剤および治療剤、ならびに、これらを製造するためのｈｉｆ経路阻害剤の使用
EP3694500A4 (en) 2017-10-10 2021-06-30 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020068986A1 (en) 2018-09-25 2020-04-02 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
JP7706758B2 (ja) 2019-03-26 2025-07-14 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
EP3962894A4 (en) 2019-05-02 2023-01-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND USES THEREOF
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
WO2022255282A1 (ja) * 2021-05-31 2022-12-08 国立大学法人大阪大学 動体視力向上用組成物
CN115105512A (zh) * 2022-08-29 2022-09-27 中山大学中山眼科中心 脱氢表雄酮在制备预防、治疗眼部近视的药物中的用途及其剂型和制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
SE8305864D0 (sv) * 1983-10-25 1983-10-25 L E Medical Ogondroppar
US4617299A (en) * 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR960002739B1 (ko) * 1990-08-31 1996-02-26 데루오 니시다 각막 장해 치료제
US5506220A (en) * 1991-06-18 1996-04-09 Laboratoire Theramex Sa Anti-glaucomatous pharmaceutical composition and the process for obtaining them
JP2531558B2 (ja) * 1991-08-17 1996-09-04 ルブキン、バージニア ドライアイ症処置用の性ステロイド膏薬、同薬の調製法および適用法
AU678961B2 (en) * 1991-11-22 1997-06-19 Alcon Laboratories, Inc. Angiostatic steroids
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
EP0674528A4 (en) * 1992-12-02 1996-06-26 Insite Vision Inc DRUG DELIVERY SYSTEM BASED ON CYCLODEXTRIN AND A POLYMER.
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
US6142989A (en) * 1993-05-03 2000-11-07 O'donnell, Jr.; Francis E. Apparatus and method for customized laser correction of refractive error
US5556395A (en) * 1993-05-07 1996-09-17 Visx Incorporated Method and system for laser treatment of refractive error using an offset image of a rotatable mask
NZ270077A (en) * 1993-12-14 1996-04-26 Lilly Co Eli Aqueous complexes of benzothiophenes and cyclodextrins
US5521168A (en) * 1994-10-13 1996-05-28 Alcon Laboratories, Inc. Estrogen metabolites for lowering intraocular pressure
JP4313435B2 (ja) * 1995-07-24 2009-08-12 トラスティーズ オブ ボストン ユニバーシティー プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制
DE69707509D1 (de) * 1996-07-12 2001-11-22 Novo Nordisk As 2-phenyl-3-azoylbenzothiophene zur minderung des intraokularen drucks
EP1506775A1 (en) * 1996-07-22 2005-02-16 Renovo Limited Use of sex steroid function modulators to treat wounds and fibrotic disorders
AUPO427196A0 (en) * 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
EP1061943B1 (en) * 1998-03-12 2002-10-23 Genentech, Inc. Use of fgf-5 polypeptides for preventing the death of retinal neurons and treating ocular diseases
EP1142585A4 (en) * 1999-01-12 2005-08-03 Santen Pharmaceutical Co Ltd DRUGS AGAINST CORNEAL DISORDERS
US20010041745A1 (en) * 1999-04-08 2001-11-15 Bryant Henry Uhlman Methods for increasing levels of acetylcholine
WO2000076522A1 (en) * 1999-06-11 2000-12-21 Watson Pharmaceuticals, Inc. Administration of non-oral androgenic steroids to women
AU1735001A (en) * 1999-12-10 2001-06-18 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
US6605640B2 (en) * 2001-01-31 2003-08-12 Gerard M. Nolan Method of treating certain eye diseases
AU2002228891A1 (en) 2000-11-17 2002-05-27 Washington University Cytoprotective estrogen derivatives
KR20030084926A (ko) * 2001-02-13 2003-11-01 디알. 게르하르트만, 켐.-팜. 파브릭게엠베하 눈의 퇴행성신경질환의 치료를 위한가바-수용체-모듈레이터
TWI320712B (en) * 2001-09-05 2010-02-21 Alcon Inc The use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma
EP2305308A1 (en) * 2003-04-18 2011-04-06 Advanced Medicine Research Institute Remedies for diseases to be applied to eye

Also Published As

Publication number Publication date
WO2004091630A1 (ja) 2004-10-28
EP2289488A3 (en) 2011-03-30
EP2301549A1 (en) 2011-03-30
EP2289488A2 (en) 2011-03-02
EP2311465A1 (en) 2011-04-20
EP2292239A3 (en) 2011-03-30
DE602004030103D1 (de) 2010-12-30
AU2004229291A1 (en) 2004-10-28
ATE488240T1 (de) 2010-12-15
EP1621199B1 (en) 2010-11-17
JP2010184927A (ja) 2010-08-26
EP1621199B8 (en) 2011-01-19
EP2292239A2 (en) 2011-03-09
JP4564920B2 (ja) 2010-10-20
EP1621199A4 (en) 2006-09-27
EP1621199A1 (en) 2006-02-01
JPWO2004091630A1 (ja) 2006-08-17
CA2527175A1 (en) 2004-10-28
EP2305308A1 (en) 2011-04-06

Similar Documents

Publication Publication Date Title
WO2004091630A8 (ja) 眼に適用する疾患治療剤
MA28337A1 (fr) Derives de l'acide 7-phenylamino-4-quinolone-3-carboxylique, methodes pour leur production et leur utilisation en tant que medicaments
NZ586588A (en) Formulation of ( follice stimulating hormone) fsh and varients with benzalkonium chloride and benzyl alcohol
WO2006015259A3 (en) Compounds and compositions as modulators of steroid hormone nuclear receptors
WO2006060618A3 (en) Topical nepafenac formulations
WO2007044693A3 (en) Multi-functional ionic liquid compositions
WO2012015810A3 (en) Pharmaceutical compositions containing pemetrexed having extended storage stability
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
WO2011014850A3 (en) Topical eutectic-based formulations
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
AR047928A1 (es) Derivados de tetrahidropiridoindol
BRPI0409133B8 (pt) preparações farmacêuticas estavéis compreendendo metilnaltrexona
CU20130142A7 (es) Preparación de gadobutrol de alta pureza
IL176416A (en) History of Nitroxy prostaglandin, pharmaceutical preparations containing them, and their use in the preparation of the drug for the treatment of glaucoma or intraocular pressure
WO2014096985A3 (en) A stable aqueous composition comprising human insulin or an analogue or derivative thereof
BR112015021470A2 (pt) conjugado de polímero para administração de um agente bioativo
CL2008000594A1 (es) Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades.
WO2010021607A3 (en) Pharmaceutical formulation
WO2007092065A3 (en) Compounds and compositions as lxr modulators
WO2016130800A3 (en) Pharmaceutical compositions comprising perillyl alcohol derivatives
HK1231376A1 (zh) 局部制剂及其应用
HK1216839A1 (zh) 调整释放制剂
IL179012A (en) A drug containing cetirizine for the treatment of nasal inflammation, a process for its preparation and use
WO2010080414A3 (en) Substituted fno (2-[furan-2-yl] naphthalen-1-ol) derivatives as anti-cancer agents
MX2015005832A (es) Dispensador plegable de un solo uso para una composicion adhesiva de tratamiento de tocador.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005505476

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11252013

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004229291

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004727990

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 5311/DELNP/2005

Country of ref document: IN

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 44/2004 UNDER (30) REPLACE "2004-004709" BY "PCT/JP2004/0004709"

WWE Wipo information: entry into national phase

Ref document number: 2527175

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2004229291

Country of ref document: AU

Date of ref document: 20040416

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004229291

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004727990

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11252013

Country of ref document: US